Loading
Inflammasome and Immune Disorders / Protease and Inhibitor Mechanisms / Adipokines, Inflammation, and Metabolic Diseases · Journal article
BMC Cancer · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a hypothesis-generating bioinformatics and cell-culture study proposing HLTF as a regulator of PANoptosis-driven prostate cancer proliferation and EGCG as a putative inhibitor. The work is mechanistic and exploratory; it does not demonstrate clinical benefit or in vivo efficacy and requires preclinical and clinical validation before any therapeutic claims can be supported.
Bioinformatics model development with in vitro cell-line validation and computational docking. Prostate cancer tissue samples and prostate adenocarcinoma (PRAD) cell lines; no human clinical trial cohort described. Intervention: HLTF knockdown in PRAD cells; EGCG exposure to HLTF-overexpressing PRAD cells. Compared with: HLTF-overexpressing PRAD cells; high PANS group versus low PANS group.
Low PANS group exhibited higher TIDE scores than high PANS group, suggesting less favorable response to immune checkpoint blockade HLTF is highly expressed in prostate cancer cells Knockdown of HLTF reduced proliferation capacity of prostate cancer cells
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work is preclinical and does not yet inform clinical practice. HLTF and EGCG warrant further investigation in controlled preclinical and animal models before consideration for clinical translation.
Early-stage mechanistic study combining bioinformatics clustering, cell-line experiments, and computational docking without clinical validation or in vivo efficacy data for proposed HLTF-targeting interventions.
As stated by the source record.
This work is preclinical and does not yet inform clinical practice. HLTF and EGCG warrant further investigation in controlled preclinical and animal models before consideration for clinical translation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Accumulating evidence indicates that pan-apoptosis plays a significant role in tumour progression, highlighting the importance of determining its relevance to tumour prognosis and treatment. This study aims to classify the molecular patterns of pan-apoptosis and explore the molecular and tumour microenvironment characteristics to predict the prognosis of prostate cancer. Prostate cancer samples were clustered into two subtypes based on the expression matrix of pan-apoptosis-related genes. Pan-apoptosis-related genes were identified using differential gene expression analysis. A novel model was developed incorporating the four core genes. Validation of the model was conducted through EdU assays, quantitative real-time PCR, and Western blotting. The pan-apoptosis model was successfully developed, demonstrating robust performance in prognostic prediction. Notably, the low PANS group exhibited higher TIDE scores than the high PANS group, suggesting a potentially less favorable response to immune checkpoint blockade therapy in the low-PANS population. Furthermore, our study revealed that HLTF was highly expressed in PRAD cell. Meanwhile, the function of HLTF in PRAD has been explored and the results showed the proliferation capacity of PRAD cell diminished following the knockdown of HLTF. Furthermore, our study uncovered a potential mechanistic link, suggesting that HLTF may regulate PANoptosis through the modulation of ZBP1-PANoptosome assembly. Molecular docking analysis identified several compounds and drugs that target HLTF. Among them, the small-molecule compound EGCG was found to interact with the HLTF protein and effectively reverse the enhanced proliferative capacity of prostate adenocarcinoma (PRAD) induced by HLTF overexpression. Our study investigated the mechanism of action of PANoptosis and emphasised its potential clinical applications. The PANoptosis model could accurately predict the prognosis of patients with PRAD and guide the treatment. HLTF could regulate the assembly of ZBP1-PANoptosome, thereby influencing the proliferation of prostate cancer cells. Additionally, EGCG and other HLTF-binding compounds merit further preclinical evaluation as potential therapeutic leads.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.